- CA$29.26m
- CA$121.11m
Brief: Resverlogix Announces Withdrawal Of Public Offering Of Units
Brief: Resverlogix Advances Us$30 Million Loan Closing Documentation
Brief: Resverlogix Announces Proposed Offering Of Units
Brief: Resverlogix Corp Announces TSX Review Update
Brief: Resverlogix Says Accepted Commitment Letter For $30 Mln Senior Secured Loan
Brief: Resverlogix Exceeds Full Enrollment For The Pivotal Phase 3 Betonmace Clinical Trial
Brief: Resverlogix Announces Recommendation From Data Safety Monitoring Board For Study Of Apabetalone
Brief: Resverlogix Receives FDA Protocol Acceptance For Ongoing Phase 3 Betonmace Trial
Brief: Resverlogix, Medison Pharma Ltd Announce Strategic Licensing Agreement
Brief: Resverlogix announces fifth positive recommendation from Data Safety Monitoring Board for Apabetalone
Brief: Resverlogix Corp entered into a Right of First Refusal Agreement with Hepalink USA Inc
Brief: Resverlogix reports $87 mln private placement with Shenzhen Hepalink
Brief: Shenzhen Hepalink Pharmaceutical to invest in Canada's Resverlogix Corp
Brief: Resverlogix closes extension of maturity date of loan and announces private placement
Brief: Successful CANTOS Inflammation Trial supports rationale for Resverlogix' ongoing betonmace trial
Brief: Resverlogix announces extension of maturity date of loan and expression of interest on strategic transaction
Brief: Resverlogix receives approval pathway from the FDA as to the inclusion of USA patients in the phase 3 betonmace trial
Brief: Resverlogix randomizes first patient in Taiwan portion of Betonmace clinical trial
Brief: Resverlogix announces fourth positive recommendation from DSMB